Supplemental Online Content

Greene SK, Levin-Rector A, Luoma E, et al. Assessment of COVID-19 hospitalization risk during SARS-CoV-2 Omicron relative to Delta variant predominance, New York City, August 2021–January 2022.

eMethods

- **eTable 1.** Characteristics of New York City residents with Delta and Omicron SARS-CoV-2 infections based on sequencing result, diagnosed July 2021–January 2022.
- **eTable 2**. Relative risks of hospitalization by diagnosis with COVID-19 during periods of Omicron compared with Delta predominance, overall and according to vaccination status, New York City, August 2021–January 2022.
- **eTable 3.** Relative risks of death by diagnosis with COVID-19 during periods of Omicron compared with Delta predominance, overall and according to vaccination status, New York City, August 2021–January 2022.
- **eFigure 1.** Eligibility for secondary analysis of Delta and Omicron infections based on wholegenome sequencing result.
- **eFigure 2.** Relative risks of (A) hospitalization with COVID-19-like illness presentation and (B) death with COVID-19 indicated on the death certificate, by diagnosis during periods of Omicron compared with Delta predominance overall and according to vaccination status, New York City, August 2021–January 2022.
- **eFigure 3.** Relative risks of COVID-19 hospitalization and death for patients with Omicron compared with Delta sequencing results, overall and according to vaccination status, New York City, July 2021–January 2022.

This supplemental material has been provided by the authors to give readers additional information about their work.

eMethods.

Sensitivity analyses

For a more specific exposure definition, we alternatively identified patients diagnosed during July 1, 2021–January 31, 2022 and with sequencing results indicating infection with Delta (n=25,272) or Omicron (n=29,866) variant (eFigure 1).

For a more specific hospitalization definition, we restricted to the subset of COVID-19 hospitalizations for which, based on syndromic surveillance, patients had presented to the emergency department with COVID-19-like illness within +/- 14 days of diagnosis. COVID-19-like illness was defined as chief complaint or ICD-10 codes for pneumonia or influenza-like illness (fever, cough, sore throat, and/or respiratory illness), and without regard to the COVID-19 ICD-10 code.

For a more specific deaths definition, we restricted to the subset with COVID-19 indicated on the death certificate.

Exclusions

Exclusion criteria included patients with >1 diagnosis >90 days apart during the study period, such that each eligible patient had only Delta or Omicron infection (Figure 1). Additionally, on December 16, 2021, the Advisory Committee on Immunization Practices preferentially recommended the mRNA COVID-19 vaccines.¹ The small percentage of study participants whose first COVID-19 vaccine dose was Ad26.COV2 from Janssen (Johnson & Johnson) were excluded (4% [27,408/674,260], Figure 1). With the operational benefit of requiring only one dose, this vaccine had been differentially administered to certain populations, e.g., homebound seniors.² These vaccine recipients likely disproportionately had underlying conditions associated with COVID-19 hospitalization and death, and including them without accounting for these unobserved confounders could have biased results.

- Oliver SE, Wallace M, See I, et al. Use of the Janssen (Johnson & Johnson) COVID-19 vaccine: updated interim recommendations from the Advisory Committee on Immunization Practices - United States, December 2021. MMWR Morb Mortal Wkly Rep. 2022;71(3):90-95.
- 2. The City of New York Office of the Mayor. Vaccine for all: City begins vaccination for homebound New Yorkers. Mar 4, 2021. <u>https://www1.nyc.gov/office-of-the-mayor/news/155-21/vaccine-all-city-begins-vaccination-homebound-new-vorkers</u>. Accessed Feb 2, 2022.

eTable 1. Characteristics of New York City residents with Delta and Omicron SARS-CoV-2 infections based on sequencing result, diagnosed July 2021–January 2022.

		f SARS-CoV-2 ction	Hospit	alized	Died		
	Omicron	Delta	Omicron	Delta	Omicron	Delta	
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	
Total	29,866	25,272	2,042	1,780	446	331	
Gender							
Female	16,182	13,273	1,065	925 (52.0%)	181	152	
i onalo	(54.2%)	(52.5%)	(52.2%)	020 (02.070)	(40.6%)	(45.9%	
Male	13,250	11,957	977 (47.8%)	854 (48.0%)	265	179	
	(44.4%)	(47.3%)	((59.4%)	(54.1%	
Unknown/missing	434 (1.5%)	42 (0.2%)	0 (0.0%)	1 (0.1%)	0 (0.0%)	0 (0.0%	
Age group (years)							
<10	2,998	2,612 (10.3%)	126 (6.2%)	43 (2.4%)	0 (0.0%)	0 (0.0%	
<10	(10.0%)	2,012 (10.370)	120 (0.270)	7J (2.470)	0 (0.0 %)	0 (0.0 %	
10–19	3,049	2,906 (11.5%)	70 (3.4%)	48 (2.7%)	0 (0.0%)	0 (0.0%	
10 13	(10.2%)	2,000 (11.070)	10 (0.470)	40 (2.170)	0 (0.070)	0 (0.070	
20–29	5,771	5,087 (20.1%)	158 (7.7%)	133 (7.5%)	7 (1.6%)	1 (0.3%	
20 20	(19.3%)	0,007 (20.170)	100 (111 /0)	100 (1.070)	/ (1.070)	1 (0.070	
30–39	5,766	5,607 (22.2%)	219 (10.7%)	225 (12.6%)	13	12	
	(19.3%)	-,,	,	((2.9%)	(3.6%	
40–49	3,963	3,391 (13.4%)	142 (7.0%)	242 (13.6%)	19	24	
	(13.3%)	, (,	()	· · · · ·	(4.3%)	(7.3%	
50–59	3,457	2,606 (10.3%)	226 (11.1%)	285 (16.0%)	40	4;	
	(11.6%)				(9.0%)	(13.0%	
60–69	2,639 (8.8%)	1,755 (6.9%)	324 (15.9%)	298 (16.7%)	77	7	
					(17.3%)	(21.5%	
70–79	1,270 (4.3%)	828 (3.3%)	354 (17.3%)	262 (14.7%)	100	78	
					(22.4%)	(23.6%	
80–89	699 (2.3%)	369 (1.5%)	305 (14.9%)	176 (9.9%)	123	59	
				(()	(27.6%)	(17.8%	
≥90	254 (0.9%)	111 (0.4%)	118 (5.8%)	68 (3.8%)	67	43	
	0 (0 00()	0 (0 00()	0 (0 00()	0 (0 00()	(15.0%)	(13.0%	
Unknown/missing	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%	
Race/ethnicity							
Asian/Pacific Islander	3,648	2,048 (8.1%)	168 (8.2%)	118 (6.6%)	43	20	
	(12.2%)	. ,	, , ,	. ,	(9.6%)	(6.0%	
Black/African American	4,816	5,014 (19.8%)	690 (33.8%)	592 (33.3%)	138	11 [.]	
	(16.1%)	-		-	(30.9%)	(33.5%	
Hispanic/Latino	7,653	5,967 (23.6%)	490 (24.0%)	466 (26.2%)	96	77	
	(25.6%)				(21.5%)	(23.3%	
White	6,712	7,280 (28.8%)	430 (21.1%)	432 (24.3%)	142	102	
	(22.5%)				(31.8%)	(30.8%	
Other	200 (0.7%)	537 (2.1%)	23 (1.1%)	58 (3.3%)	(0.50()	12	
					(2.5%)	(3.6%	

Unknown	6,837	4,426 (17.5%)	241 (11.8%)	114 (6.4%)	16	9 (2.7%
	(22.9%)				(3.6%)	
Congregate setting resident ^a						
Yes	347 (1.2%)	119 (0.5%)	104 (5.1%)	59 (3.3%)	60 (13.5%)	30 (10.9%
No	28,628 (95.9%)	24,951 (98.7%)	1,856 (90.9%)	1,713 (96.2%)	379 (85.0%)	299 (89.1%
Unknown/missing	891 (3.0%)	202 (0.8%)	82 (4.0%)	8 (0.4%)	7 (1.6%)	0 (0.0%
Census tract-based poverty level ^b						
Low	8,801 (29.5%)	7,816 (30.9%)	343 (16.8%)	371 (20.8%)	89 (20.0%)	77 (23.3%
Medium	9,254 (31.0%)	7,830 (31.0%)	708 (34.7%)	562 (31.6%)	169 (37.9%)	103 (31.1%
High	5,358 (17.9%)	4,538 (18.0%)	386 (18.9%)	380 (21.3%)	77 (17.3%)	56 (16.9%)
Very high	5,094 (17.1%)	4,255 (16.8%)	498 (24.4%)	420 (23.6%)	101 (22.6%)	87 (26.3%
Unknown/missing	1,359 (4.6%)	833 (3.3%)	107 (5.2%)	47 (2.6%)	10 (2.2%)	8 (2.4%
Prior COVID-19 diagnosis						
Yes	2,137 (7.2%)	1,251 (5.0%)	130 (6.4%)	24 (1.3%)	19 (4.3%)	3 (0.9%
No	27,729 (92.8%)	24,021 (95.0%)	1,912 (93.6%)	1,756 (98.7%)	427 (95.7%)	328 (99.1%
Days since prior diagnosis						
91–180	153 (7.2%)	99 (7.9%)	12 (9.2%)	10 (41.7%)	3 (15.8%)	2 (66.7%
180–269	166 (7.8%)	218 (17.4%)	10 (7.7%)	8 (33.3%)	1 (5.3%)	0 (0.0%)
270–359	764 (35.8%)	203 (16.2%)	47 (36.2%)	2 (8.3%)	3 (15.8%)	0 (0.0%)
360–449	533 (24.9%)	637 (50.9%)	30 (23.1%)	1 (4.2%)	2 (10.5%)	0 (0.0%
≥450	521 (24.4%)	93 (7.4%)	31 (23.8%)	3 (12.5%)	10 (52.6%)	(33.3%
Number of COVID-19 vaccine doses						
0	10,863 (36.4%)	16,006 (63.3%)	1,105 (54.1%)	1,405 (78.9%)	271 (60.8%)	258 (77.9%
1	1,502 (5.0%)	680 (2.7%)	87 (4.3%)	53 (3.0%)	21 (4.7%))10 (3.0%

^a Congregate settings defined as having a residential address as of diagnosis of a nursing home, jail, or prison. ^b Low poverty defined as <10% of residents below the federal poverty level, medium as 10% to <20%, high as 20 to <30%, and very high as ≥30%.

2	13,129	8,443 (33.4%)	693 (33.9%)	310 (17.4%)	119	58
	(44.0%)				(26.7%)	(17.5%)
3	4,372	143 (0.6%)	157 (7.7%)	12 (0.7%)	35	5 (1.5%)
	(14.6%)				(7.8%)	
Days since 14 days after most recent COVID-19 vaccine dose						
<90	6,906	1,788 (19.3%)	263 (28.1%)	82 (21.9%)	46	17
	(36.3%)	, , ,	()	()	(26.3%)	(23.3%)
90–179	3,295	3,889 (42.0%)	180 (19.2%)	133 (35.5%)	24	27
	(17.3%)			(, , , , , , , , , , , , , , , , , , ,	(13.7%)	(37.0%)
180–269	6,735	3,245 (35.0%)	350 (37.4%)	141 (37.6%)	63	27
	(35.4%)		. ,	. ,	(36.0%)	(37.0%)
≥270	1,967	314 (3.4%)	141 (15.0%)	16 (4.3%)	42	1 (1.4%)
	(10.4%)				(24.0%)	

eTable 2. Relative risks of hospitalization by diagnosis with COVID-19 during periods of Omicron compared with Delta predominance, overall and according to vaccination status, New York City, August 2021–January 2022.

	-	Not hospitalized	Crude RR (95% CI)	p value	Adjusted RR (95% CI)	p value
Variant						
Delta	8,268/158,799 (5.2%)	150,531/158,799 (94.8%)	1 (ref)		1 (ref)	
Omicron	16,025/488,053 (3.3%)	472,028/488,053 (96.7%)	0.62 (0.55, 0.70)	<.001	0.72 (0.63, 0.82)	<.001
By vaccination status						
None or only one dose				<.001		<.001
Delta	6,391/107,356 (6.0%)	100,965/107,356 (94.0%)	1 (ref)		1 (ref)	
Omicron	8,837/218,185 (4.1%)	209,348/218,185 (95.9%)	0.68 (0.66, 0.70)	<.001	0.65 (0.63, 0.67)	<.001
Two doses						
Delta	1,849/50,897 (3.6%)	49,048/50,897 (96.4%)	1 (ref)		1 (ref)	
Omicron	5,558/200,284 (2.8%)	194,726/200,284 (97.2%)	0.76 (0.73, 0.80)	<.001	0.98 (0.93, 1.04)	0.58
Three doses						
Delta	28/546 (5.1%)	518/546 (94.9%)	1 (ref)		1 (ref)	
Omicron	1,630/69,584 (2.3%)	67,954/69,584 (97.7%)	0.46 (0.32, 0.66)	<.001	0.58 (0.40, 0.84)	0.004
Restricted to Omicron						
None or only one dose	8,837/218,185 (4.1%)	209,348/218,185 (95.9%)	1 (ref)		1 (ref)	
Two doses	5,558/200,284 (2.8%)	194,726/200,284 (97.2%)	0.69 (0.66, 0.71)	<.001	0.77 (0.72, 0.82)	<.001
Three doses	1,630/69,584 (2.3%)	67,954/69,584 (97.7%)	0.58 (0.55, 0.61)	<.001	0.37 (0.35, 0.40)	<.001

Patients with Delta infection and 0–1 doses as referent:

	Not hospitalized		Hospitalized	•		Crude RR (95% CI)		Adjusted RR (95% CI)		p value
	Delta	Omicron	Delta	Omicron	Delta	Omicron		Delta	Omicron	
None	100,965/310,313	209,348/310,313	6,391/15,228	8,837/15,228		0.68			0.65	
or one	(32.5%)	(67.5%)	(42.0%)	(58.0%)	1 (ref)	(0.66,	<.001	1 (ref)	(0.63,	<.001
dose	, , , , , , , , , , , , , , , , , , ,	, , , , , , , , , , , , , , , , , , ,	x ,	· · ·	· · ·	0.70)		· · ·	0.67)	
Two	49,048/243,774	194,726/243,774	1,849/7,407	5,558/7,407	0.61	0.47		0.51	0.50	
doses	(20.1%)	(79.9%)	(25.0%)	(75.0%)	(0.58,	(0.45,		(0.47,	(0.47,	
	. ,	· · · ·	. ,	. ,	0.64)	0.48)		0.55)	0.54)	
Three	518/68,472	67,954/68,472	28/1,658	1,630/1,658	0.86	0.39		0.42	0.24	
doses	(0.8%)	(99.2%)	(1.7%)	(98.3%)	(0.60,	(0.37,		(0.29,	(0.23,	
	· · /	, <i>,</i>	· · ·	. ,	1.24)	0.42)		0.62)	0.26)	


eTable 3. Relative risks of death by diagnosis with COVID-19 during periods of Omicron compared with Delta predominance, overall and according to vaccination status, New York City, August 2021–January 2022.

	Death	No death	Crude RR (95% CI)	p value	Adjusted RR (95% CI)	p value
Variant						
Delta	1,196/158,799 (0.8%)	157,603/158,799 (99.2%)	1 (ref)		1 (ref)	
Omicron	2,696/488,053 (0.6%)	485,357/488,053 (99.4%)	0.66 (0.49, 0.89)	.006	0.81 (0.58, 1.13)	.22
By vaccination status						
None or only one dose				.11		<.001
Delta	890/107,356 (0.8%)	106,466/107,356 (99.2%)	1 (ref)		1 (ref)	
Omicron	1,534/218,185 (0.7%)	216,651/218,185 (99.3%)	0.85 (0.78, 0.92)	<.001	0.68 (0.63, 0.74)	<.001
Two doses						
Delta	301/50,897 (0.6%)	50,596/50,897 (99.4%)	1 (ref)		1 (ref)	
Omicron	865/200,284 (0.4%)	199,419/200,284 (99.6%)	0.73 (0.64, 0.83)	<.001	1.09 (0.95, 1.25)	.22
Three doses						
Delta	5/546 (0.9%)	541/546 (99.1%)	1 (ref)		1 (ref)	
Omicron	297/69,584 (0.4%)	69,287/69,584 (99.6%)	0.47 (0.19, 1.12)	.09	0.72 (0.27, 1.93)	.52
Restricted to Omicron						
None or only one dose	1,534/218,185 (0.7%)	216,651/218,185 (99.3%)	1 (ref)		1 (ref)	
Two doses	865/200,284 (0.4%)	199,419/200,284 (99.6%)	0.61 (0.57, 0.67)	<.001	0.82 (0.69, 0.98)	.03
Three doses	297/69,584 (0.4%)	69,287/69,584 (99.6%)	0.61 (0.54, 0.69)	<.001	0.39 (0.31, 0.47)	<.001


Patients with Delta infection and 0–1 doses as referent:

	No death		Death	Death		Crude RR (95% CI)		Adjusted RR (95% Cl)		p value
	Delta	Omicron	Delta	Omicron	Delta	Omicron		Delta	Omicron	
None or one dose	106,466/323,117 (32.9%)	216,651/323,117 (67.1%)	890/2,424 (36.7%)	1,534/2,424 (63.3%)	1 (ref)	0.85 (0.78, 0.92)	.11	1 (ref)	0.68 (0.63, 0.74)	<.001
Two doses	50,596/250,015 (20.2%)	199,419/250,015 (79.8%)	301/1,166 (25.8%)	865/1,166 (74.2%)	0.71 (0.63, 0.81)	0.52 (0.47, 0.57)		0.51 (0.42, 0.63)	0.56 (0.46, 0.68)	
Three doses	541/69,828 (0.8%)	69,287/69,828 (99.2%)	5/302 (1.7%)	297/302 (98.3%)	1.10 (0.46, 2.65)	0.51 (0.45, 0.59)	•	0.36 (0.13, 0.99)	0.26 (0.21, 0.33)	

eFigure 1. Eligibility for secondary analysis of Delta and Omicron infections based on whole-genome sequencing result.




eFigure 2. Relative risks of (A) hospitalization with COVID-19-like illness presentation and (B) death with COVID-19 indicated on the death certificate, by diagnosis during periods of Omicron compared with Delta predominance overall and according to vaccination status, New York City, August 2021–January 2022.



9

eFigure 3. Relative risks of COVID-19 hospitalization and death for patients with Omicron compared with Delta sequencing results, overall and according to vaccination status, New York City, July 2021–January 2022.

(A) Hospitalization



(B) Death